EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, has appointed Wei-Wu He, Ph.D, executive chairman of its board of directors, and Tak W. Mak, Ph.D, as member of the board of directors.
Dr. Wei-Wu He is currently CEO and chairman of OriGene Technologies. He also is the founder and general partner of Emerging Technology Partners, a life sciences focused venture fund. He has also held positions at Human Genome Sciences, Massachusetts General Hospital and Mayo Clinic. He has been involved in founding and funding over 20 biotech companies throughout his career.
Dr. Tak W. Mak is currently the director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Hospital and a professor in the department of medical biophysics and department of immunology, University of Toronto. He is best known as the leading scientist of the group that first cloned the genes of the human T-cell antigen receptor. Mak has held director and vice president positions at Amgen and Amgen Institute and has experience as a venture capitalist.